A polymorphic marker Val109Asp in the omentin gene are associated with abdominal obesity in the Kyrgyz population

Aim — in this study, we investigated whether polymorphisms Val109Asp in the omentin gene are associated with abdominal obesity in the Kyrgyz population.

Material and methods. We genotyped 297 nonrelated adults Kyrgyz individuals. 127 patients (male — 46, female — 81, average age — 53±7,0) with abdominal obesity (elevated waist circumferences ≥102 cm for male subjects and ≥ 88 cm for female) and 170 non-obese control subjects (male — 107, female — 63, average age 51±9). Val109Asp polymorphisms analysis in the omentin gene were performed by PCR-RFLP method.

Results. There were significant differences in genotype distributions of rs2274907 between the obese and control cohorts (p=0.01). Frequencies of Asp109Asp, Val109Asp and Val109Val genotypes among patients with abdominal obesity were 48, 40 and 12%, respectively, that differed from those among controls (Asp109Asp — 53%, Val109Aspl — 43% and Val109Val — 4%); there was significant difference in genotype frequencies between two groups (χ²=6,29; p=0,043). Homozygous genotype Val109Val was more frequent in the obese than non-obese group. The genotype Val109Val of omentin gene is associated with a high risk of developing abdominal obesity in the Kyrgyz population (OR=3,12; 95% CI 1,23—7,90). Homozygous genotype Asp109Asp, reduces the risk of developing abdominal obesity (OR=0,82; 95% CI 0,53—1,30). The allelic variants of the polymorphisms Val109Asp in the omentin gene were not found to be associated with abdominal obesity.

Conclusion. There is significant association between Val109Asp polymorphism in omentin gene and abdominal obesity in the Kyrgyz Population. An increased risk of abdominal obesity associated with homozygous genotype — Val109Val in omentin gene.

1. Дедов И.И. Морбидное Ожирение. — М.: Миа. 2014. [Dedov II. Morbidnoe Ozhirenie. Moscow: Mia. 2014. (In Russ).].

2. Who. Obesity And Overweight. Who Media Centre. Fact Sheet N°311; 2015.

3. Нацстатком Кыргызской Республики. Уровень Жизни Населения Кыргызской Республики 2010—2014. Годовая Публикация. — Бишкек, 2015. — 132 C. [Nacstatkom Kyrgyzskoj Respubliki. Uroven Zhizni Naselenija Kyrgyzskoj Respubliki 2010—2014. Godovaja Publikacija. Bishkek 2015;132. (In Russ).]. Url: http://www.stat.kg

4. Кунцевич А.К. Риск метаболического синдрома и питание // Ожирение и метаболизм. – 2015. – Т.12. — №1. — C.3-10. [Kuntsevich AK. The risk of metabolic syndrome and nutrition. Obesity and metabolism. 2015;12(1):3-10. (In Russ.)]. doi: 10.14341/omet20151

5. Ройтберг Г.Е. Метаболический cиндром. — М.: Медпресс-Информ. 2007. [Roytberg GE. Metabolicheskiy sindrom. Moscow: MEDpress-inform. 2007. (In Russ.)].

6. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36(7):461-470. doi: 10.1016/j.tips.2015.04.014

7. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. AJP: Endocrinology and Metabolism. 2006;290(6):E1253-E1261. doi: 10.1152/ajpendo.00572.2004

8. De Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655-1661. doi: 10.2337/db06-1506

9. Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 dy insulin and glucose. Diabetes. 2008;57(4):801-808. doi: 10.2337/db07-0990

10. Вербовой А.Ф., Соломонова E.C., Пашенцева А.В. Лептин, резистин и оментин у пациентов с нарушенной толерантностью к глюкозе и сахарным диабетом 2-го типа. // Известия высших учебных заведений. Поволжский регион. Медицинские науки –– 2012. — №3. — C.52-59. [Verbovoi AF, Solomonova ES, Pashenceva AV. Leptin, rezistin I omentin u pacientov s narushennoj tolerantnost’ju k gljukoze i saharnym diabetom 2-go tipa. Izvestija vysshih uchebnyh zavedenij. Povolzhskij region. Medicinskie Nauki. 2012;(3):52-59. (In Russ.)].

11. Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011;12(1):60. doi: 10.1186/1471-2350-12-60

12. Abd-Elbaky AE, Abo-Elmatty DM, Mesbah NM, Ibrahim SM. Omentin and apelin concentrations in relation to obesity, diabetes mellitus type two, and cardiovascular diseases in Egyptian population. International Journal of Diabetes in Developing Countries. 2015;36(1):52-58. doi: 10.1007/S13410-015-0416-y

13. Schäffler A, Neumeier M, Herfarth H, et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005;1732(1-3):96-102. doi: 10.1016/j.bbaexp.2005.11.005

14. Schaffler A, Zeitoun M, Wobser H, et al. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovasc Diabetol. 2007;6:3. doi: 10.1186/1475-2840-6-3

15. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63(4):250-259. doi: 10.1016/J.Jjcc.2013.11.006

16. Bahadori M, Kohan L, Jafari N. Association of assessment between Val109Asp omentin gene and obesity in Iranian women. Iranian Journal of Diabetes and Metabolism. 2015;14(2):127-132. http://ijdld.tums.ac.ir/browse.php?a_code=A-10-1-117&slc_land=en&sid=1

17. Turan H, Yaykasli KO, Soguktas H, et al. Omentin serum levels and omentin gene Val109Asp polymorphism in patients with psoriasis. Int J Dermatol. 2014;53(5):601-605. doi: 10.1111/ijd.12306

18. Splichal Z, Bienertova-Vasku J, Novak J, et al. The common polymorphism Val109Asp in the omentin gene is associated with daily energy intake in the Central-European population. Nutr Neurosci. 2015;18(1):41-48. doi: 10.1179/1476830513y.0000000100

19. An increased risk of breast cancer associated with Val109Asp polymorphism in omentin gene. International Journal of Biosciences (IJB). 2014;5(1):429-434. doi: 10.12692/jb/5.1.429-434

20. Halabis M, Dziedzic M, Warchulinska J, et al. Omentin — a new adipokine with many roles to play. Current Issues in Pharmacy and Medical Sciences. 2015;28(3). doi: 10.1515/cipms-2015-0067

21. Zhou J-Y, Chan L, Zhou S-W. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol. 2014;12(1):136-143. doi: 10.2174/1570161112999140217095038